More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.13B
EPS
-4.61
P/E ratio
--
Price to sales
--
Dividend yield
--
Beta
2.440174
Previous close
$8.27
Today's open
$8.19
Day's range
$7.81 - $8.41
52 week range
$4.88 - $15.87
show more
CEO
Kabir Nath
Employees
156
Headquarters
London,
Exchange
Nasdaq Global Select
Shares outstanding
141710353
Issue type
American Depository Receipt
Healthcare
Biotechnology & Life Sciences
Compass Pathways Completes FDA Application for Psilocybin Therapy, Prepares for Launch
Compass Pathways NASDAQ: CMPS has completed its application for U.S. approval of COMP360, its proprietary synthetic psilocybin formulation for treatment-resistant depression, and is preparing for a potential commercial launch, executives said at a company news event.
MarketBeat • Nov 12, 2026

Compass Pathways to Participate in Jefferies Global Healthcare Conference on November 18th and 19th
LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the Jefferies Global Healthcare Conference on November 18 and 19, 2026 and will participate in a fireside chat on November 18 at 9:00am GMT and a panel on November 19 at 10:30am GMT. A live audio webcast of the fireside chat will be accessible at the following link.
Business Wire • Nov 11, 2026

Compass Pathways Completes COMP360 Psilocybin New Drug Application to U.S. FDA for Treatment-Resistant Depression
LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced the Company completed its submission of a New Drug Application (NDA) to the U.S. FDA for COMP360 psilocybin, its investigational synthetic, proprietary formulation of psilocybin, for treatment-resistant depression (TRD). "People living with treatment-resistant depression have gone too long ex.
Business Wire • Nov 9, 2026

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to nine newly hired non-executive employees. The equity awards were granted on November 2, 2026, and consisted of options to purchase an aggregate of 59,275 shares and restricted share units or, in the case.
Business Wire • Nov 5, 2026

Compass Pathways to Participate in Stifel 2026 Healthcare Conference on November 11th
LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the Stifel 2026 Healthcare Conference on November 11, 2026 and will participate in a fireside chat at 8:40am ET. A live audio webcast of the fireside chat will be accessible at the following link: https://event.summitcast.com/view/4aFtJriVa3BvDmNqmfSxma/k5kw3HNd3Rg.
Business Wire • Nov 4, 2026

Compass Pathways: 3 Key Takeaways for Long-Term Investors
COMPASS will complete its New Drug Application submission within two weeks. Interventional psychiatrists surveyed show 90% willingness to prescribe COMP360.
The Motley Fool • Nov 4, 2026

Compass Pathways Q3 Earnings Call Highlights
Compass Pathways NASDAQ: CMPS said it expects to complete its rolling New Drug Application submission for COMP360, its investigational psilocybin treatment for treatment-resistant depression, within two weeks, as the company prepares for a potential U.S. launch in the first half of 2027.
MarketBeat • Nov 3, 2026

COMPASS Pathways plc (CMPS) Q3 2026 Earnings Call Transcript
COMPASS Pathways plc (CMPS) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 3, 2026

Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights
LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today reported the third quarter 2026 financial results and business highlights. "Compass is leading one of the most important advances in mental health care in decades. Millions of people living with TRD are waiting for new treatments that can deliver meaningful and lasting benefit, and we believe COMP360 ha.
Business Wire • Nov 3, 2026

1 Reason Compass Pathways Is Worth a Second Look This Month
FDA approval could provide a significant catalyst for shares. Wall Street's average price target implies approximately 95% upside.
The Motley Fool • Nov 2, 2026

¹ Disclosures

Open an M1 investment account to buy and sell COMPASS Pathways Plc commission-free¹. Build wealth for the long term using automated trading and transfers.